S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
Investing.com -- MiNK Therapeutics, Inc. (NASDAQ:INKT) stock soared 200% after the company announced a complete remission in a patient with metastatic testicular cancer following treatment with its allogeneic iNKT cell therapy, agenT-797.
The clinical-stage biopharmaceutical company published findings in Nature’s Oncogene detailing how a single infusion of agenT-797, administered alongside nivolumab, led to a complete clinical, radiologic, and biochemical remission in a patient who had previously failed multiple treatments including platinum-based chemotherapy, stem cell transplant, and various immune checkpoint inhibitors.
According to the publication, the patient has shown no evidence of disease for over two years since treatment. The therapy was reportedly well-tolerated with no cytokine release syndrome or graft-versus-host disease, with donor iNKT cells detectable up to six months after infusion.
This case adds to MiNK’s growing clinical evidence supporting agenT-797’s potential in solid tumors. The company recently presented data from its Phase 2 trial in second-line gastric cancer at the 2025 inaugural AACR Immuno-Oncology meeting, showing immune activation and extended survival beyond 12 months in several patients who were previously resistant to checkpoint inhibitors.
MiNK Therapeutics is advancing agenT-797 as an off-the-shelf, cryopreserved iNKT cell therapy for various conditions including graft-versus-host disease, solid tumors, and severe pulmonary inflammation. The company continues to enroll patients in its ongoing Phase 2 trial in gastric cancer, with additional results expected in the coming months.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.